Market Overview

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Related BMY
Morgan Stanley Downgrades Bristol-Myers On Valuation
Dan Nathan Sees Unusual Options Activity In Bristol-Myers Squibb Co
Apple Leads the Charge as Earnings Season Heats Up (Fox Business)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Bristol-Myers Squibb Co. closed on Thursday at $46.17.

Latest Ratings for BMY

DateFirmActionFromTo
Nov 2014Morgan StanleyDowngradesOverweightEqual-weight
Nov 2014JP MorganMaintainsOverweight
Oct 2014BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters